O6-methylguanine-DNA methyltransferase (MGMT) Promoter methylation is a rare event in soft tissue sarcoma

Jens Jakob1*, Maren Hille1, Christian Sauer2, Philipp Ströbel2, Frederik Wenz3 and Peter Hohenberger1

Abstract

Background: Gene silencing of O6-methylguanine–DNA methyltransferase (MGMT) by promoter methylation improves the outcome of glioblastoma patients after combined therapy of alkylating chemotherapeutic agents and radiation. The purpose of this study was to assess the frequency of MGMT promoter methylation in soft tissue sarcoma to identify patients eligible for alkylating agent chemotherapy such as temozolomide.

Findings: Paraffin tumor blocks of 75 patients with representative STS subtypes were evaluated. The methylation status of the MGMT promoter was assessed by methylation-specific polymerase-chain-reaction analysis (PCR). Furthermore, immunohistochemistry was applied to verify expression of MGMT. MGMT gene silencing was assumed if MGMT promoter methylation was present and the fraction of tumor cells expressing MGMT was 20% or less. Methylation specific PCR detected methylated MGMT promoter in 10/75 cases. Immunohistochemical staining of nuclear MGMT was negative in 15/75 cases. 6/75 tumor samples showed MGMT promoter methylation and negative immunohistochemical nuclear staining of MGMT. In none of the tested STS subtypes we found a fraction of tumors with MGMT silencing exceeding 22%.

Conclusion: MGMT gene silencing is a rare event in soft tissue sarcoma and cannot be recommended as a selection criterion for the therapy of STS patients with alkylating agents such as temozolomide.

Keywords: Soft tissue sarcoma, O6-methylguanine–DNA methyltransferase, Promoter methylation, Temozolomide, Epigenetic gene silencing, Radiation therapy

Findings

Hypothesis

Soft tissue sarcoma (STS) form a heterogeneous group of malignant tumors arising in the mesenchymal tissues. A considerable fraction of patients presents with locally advanced disease and requires multimodal therapy including chemotherapy or chemoradiation [1]. Doxorubicin and ifosfamid are generally recommended for first line systemic treatment in unresectable and/or metastatic STS. A variety of other chemotherapeutic substances have been tested in phase II trials but were never compared to standard treatment in phase III trials although some of them may be regarded as active drugs in STS [2]. Temozolomide is an oral prodrug of 3-methyl-(triazien-1yl)imidazole-4-carboximide, the active metabolite of the alkylating agent DTIC [3]. In combination with radiation therapy, temozolomide has substantially improved overall survival in glioblastoma patients and has altered the standard of care in glioblastoma treatment [4]. The activity of temozolomide in glioblastoma patients relies on gene silencing of the MGMT (O6-methylguanine–DNA methyltransferase) DNA repair gene, though [5]. In STS, temozolomide the activity of temozolomide seems to be schedule dependent [6,7]. The combination of temozolomide with irradiation which would be suitable for neoadjuvant treatment of locally advanced STS seems to be well tolerable and reveals promising response rates [8]. Further phase II and/or III trials are necessary to evaluate the efficacy of temozolomide combined with irradiation. The design of these trials must take into account MGMT gene silencing for its impact on the activity of temozolomide. The purpose of the present study was

* Correspondence: jens.jakob@umm.de
1Division of Surgical Oncology & Thoracic Surgery, Department of Surgery, University Medical Center Mannheim, University of Heidelberg, Th.Kutzer-Ufer 1-3, Mannheim 68137, Germany
Full list of author information is available at the end of the article

© 2012 Jakob et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
to determine the frequency of MGMT gene silencing in soft tissue sarcoma in order to identify patients and/or histological subtypes that may be suitable for treatment with alkylating agents and irradiation in the setting of a phase II trial.

Methods
Paraffin blocks of tumor biopsies or resections of 75 patients with representative histological sarcoma subtypes were obtained from the local tumor tissue bank (Table 1). These tumor blocks were analysed by methylation specific polymerase chain reaction (PCR) and immunohistochemistry to detect MGMT gene silencing. Ethical approval was obtained from the Medical Ethics Committee II, University of Heidelberg (Reference number 2006-154N-MA). Written informed consent was obtained from the patient for publication of this report.

For methylation specific PCR, genomic DNA was isolated from paraffin sections of the selected tissue blocks and bisulfite converted with a commercial kit (EpiTect Plus FFPE Bisulfite Kit; Qiagen; Hilden, Germany) according to the manufacturer’s instructions. The bisulfite treated DNAs were amplified by a two-step PCR approach to improve the sensitivity of detecting methylated alleles [9]. For the first round of amplification the primer sequences were 5’-GGATATGTGTTGAGTAGT-3’ (MGMT-F) and 5’-CCAAAAAACCACAACCC-3’ (MGMT-R). PCR conditions included an annealing temperature of 52°C and 40 cycles of amplification. For nested PCRs with specific primer sets for un-methylated and methylated samples 1μl of the first round amplification product was used at an annealing temperature of 60° with 35 amplification cycles. Primer sequences of MGMT for the unmethylated reaction were 5’TGG TGT TGA TGT TTG TAG GTT TTT GT-3’ (MGMT-UUP) and 5’-AAC ACA CTC TCT TCA AAA CAA AAC A-3’ (MGMT-ULP). The sequences of MGMT for the methylated reaction were 5’TGC TCG TAG GTT TTC GC-3’ (MGMT-MUP) and 5’-GCA CTC TTC CGA AAA CGA AAC G-3’ (MGMT-MLP). PCR products were separated and visualized on a QIAxcel electrophoresis system (Qiagen, Hilden, Germany). As a control we selected several cases of glioblastoma with MGMT promoter methylation and negative control samples without DNA and included both for each set of PCR.

Immunohistochemical analysis of formalin-fixed, paraffin-embedded sections of the selected tumor samples was performed according to standard protocols. The primary antibody used was MGMT Monoclonal Antibody MT 23.2 (Pierce Antibodies, IL USA) after heat antigen retrieval in pH 9 buffer (Dako, Glostrup, Denmark). Only nuclear staining was considered positive. MGMT expression was considered lost when there were 20% or less stained tumor cell nuclei.

MGMT gene silencing was assumed if methylation specific PCR detected MGMT promoter methylation AND immunohistochemistry demonstrated MGMT expression in less or equal than 20% of tumor cells. Results of these analyses are presented descriptively. Median and range are given if appropriate.

Results
Methylation specific PCR detected unmethylated MGMT promoter in 65/75 cases. In 10/75 tumor samples we found MGMT promoter methylation. Yet, in each of these cases also unmethylated MGMT promoter was detected. An example of the methylation specific PCR is given in Figure 1.

Immunohistochemical staining showed inhomogeneous expression of MGMT in most patients. Immunohistochemistry was regarded negative in 15/75 cases. An example of negative and positive staining for MGMT is depicted in Figure 2.

In 6/75 tumor samples we detected both MGMT promoter methylation and negative staining of MGMT. In none of the tested STS subtypes we found a fraction of tumors with MGMT silencing (MGMT promoter methylation and negative immunohistochemistry for MGMT) that exceeded 22% (Table 2). Of note, MGMT

| Table 1 Patient and Tumor Characteristics |
|------------------------------------------|
| N | 75 |
| Sex | | |
| Female | 33 |
| Male | 43 |
| Age (Median/range, years) | 54 (18–83) |
| Size | | |
| >10cm | 43 |
| <10cm | 32 |
| Grade | | |
| 1 | 13 |
| 2 | 24 |
| 3 | 38 |
| Histological subtype | | |
| Liposarcoma | 18 |
| MFH/NOS | 15 |
| MPNST | 10 |
| Leiomyosarcoma | 14 |
| Myxofibrosarcoma | 11 |
| Synovial sarcoma | 7 |
| Site | | |
| Lower limb | 21 |
| Upper limb | 12 |
| Retroperitoneum | 21 |
| Trunk | 12 |
| other | 9 |
promoter methylation occurred across all sarcoma subtypes, without preference for a specific entity.

Conclusions
The purpose of the present study was to determine the frequency of MGMT gene silencing in soft tissue sarcoma in order to identify STS patients and/or histological subtypes that may be suitable for treatment with alkylating agents and irradiation in a phase II clinical trial with MGMT promoter methylation being a criterion for selection or stratification. The rationale behind the study was that glioblastoma patients with MGMT gene silencing benefit from chemotherapy with the alkylating agent temozolomide in combination with radiation therapy [4].

We selected a set of paraffin blocks of representative STS subtypes and performed MGMT promoter methylation analysis and immunohistochemistry which demonstrated MGMT gene silencing in only 6/75 of the evaluated tumors. Even in those tumors where MGMT promoter methylation was present, we were able to detect tumor cells with non-methylized MGMT promoter. This phenomenon may be explained by intratumoral heterogeneity or by the detection of non-methylized MGMT promoter in tumor infiltrating lymphocytes, blood vessels or normal tissue as described before [5,10]. Furthermore the various qualitative and quantitative methods for the analysis of MGMT promoter methylation may reveal divergent results even if the sequences tested are overlapping or identical [11,12]. That was the reason to perform additional immunohistochemistry of MGMT expression in all cases of this cohort that confirmed expression of MGMT in most tumors.

Two other groups published data on MGMT gene silencing of STS in Asian populations. Kim et al. examined 62 cases of liposarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor (MPNST), malignant fibrous histiocytoma (MFH) and synovial sarcoma and reported MGMT promoter methylation in 21/62 cases [13]. Kawaguchi et al. studied the methylation of the MGMT promoter in MFH, MPNST and leiomyosarcoma and found MGMT promoter methylation in 10/65 tumor samples [14]. The rate of tumor samples examined after pretreatment was not reported. Despite differences in methods, patient populations and tumor subtypes in the present and the previously published studies, it is obvious that MGMT gene silencing is a rare event in soft tissue sarcoma. Furthermore no histological subtype can

Figure 1 Example of methylation specific PCR for unmethylated and methylated MGMT Promoter. U: unmethylated, M: methylated.

Figure 2 Example of immunohistochemistry for MGMT in two cases of STS Non Otherwise Specified (NOS). 1: positive staining, 2: negative staining.
be identified that would exhibit MGMT promoter methylation in a relevant fraction of tumors in more than one of the studies.

A selection criterion for a personalized therapy in soft tissue sarcoma should be easy and reliable to assess, discriminate between tumors that are targeted well and positive in a relevant number of patients [15]. Although MGMT gene silencing may increase the effect of alkylating agents given in combination with irradiation, we believe that the frequency of MGMT gene silencing is too low to use it as a selection or stratification criterion in a phase II trial of concomitant irradiation and alkylating agent therapy.

Competing interests
All authors declared that they have no competing interest.

Authors’ contributions
JJ, FW, PS and PH participated in the design of the study. PH took responsibility for the funding. MH, CS and PS carried out the methylation specific PCR and immunohistochemistry. JJ and MH performed the statistical analysis. JJ and PH participated in the design of the study. PH took"

Table 2 Fraction of tumors with MGMT gene silencing according to tumor subtype

| Histological subtype | MGMT promoter methylation | Negative nuclear staining of MGMT | MGMT gene silencing |
|----------------------|---------------------------|----------------------------------|---------------------|
| Liposarcoma           | 2/18                      | 3/18                             | 2/18                |
| MFH/NOS              | 1/15                      | 3/15                             | 1/15                |
| MPNST                | 3/10                      | 3/10                             | 1/10                |
| Leiomyosarcoma        | 1/14                      | 2/14                             | 1/14                |
| Synovial Sarcoma      | 1/7                       | 0/7                              | 0/7                 |
| Myxofibrosarcoma      | 2/11                      | 4/11                             | 1/11                |

References
1. Casali PG, Blay JY: Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(5):198–203.
2. Penel N, Van Gabbbeke M, Mareaud S, Ouali M, Bay JY, Hohenberger P: Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2010, 22(6):1266–1272.
3. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide; a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23(1):35–61.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987–996.
5. Hegi ME, Diserens AC, Gorlia T, Hamou M, De Tribolet N, Weller M, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997–1003.
6. Garcia Del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Boyer J, Maurel J: A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005, 104(8):1705–1712.
7. Wolf P, Judson I, Lee SM, Rodenhuis S, Nielsen OS, Buesa JM, Longtan PC, Leyvraz S, Hermans C, van Gabbbeke M, et al: Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999, 35(3):410–412.
8. Jakob J, Wenz F, Dinter DJ, Strobel P, Hohenberger P: Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009, 75(2):810–816.
9. Palmiaro WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer research 2000, 60(21):5954–5958.
10. Dunn J, Babior A, Alam F, Joyce K, Masham M, Sisbon R, Crooks D, Husband D, Shenny A, Brodbelt A, et al: Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009, 101(1):124–131.
11. Preusser M: MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histology and histopathology 2009, 24(4):511–518.
12. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature reviews Neurology 2010, 6(1):39–51.
13. Kim JI, Suh JT, Choi KJ, Kang HJ, Shin DH, Lee IS, Moon TY: Kim WT: Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations. Hum Pathol 2009, 40(7):934–941.
14. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, Tamaya S, Tateishi N, Iwamoto Y, Tsuneyoshi M: DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 2006, 19(1):106–114.
15. Scru M: History-Driven Chemotherapy in Soft Tissue Sarcomas. Curr Treat Options Oncol 2011, 12(1):52–65.

Cite this article as: Jakob et al.: O6-methylguanine-DNA methyltransferase (MGMT) Promoter methylation is a rare event in soft tissue sarcoma. Radiation Oncology 2012 7:180.